February 3, 2020 07:19 AM EST

Bristol-Myers withdraws Opdivo/Yervoy lung cancer EU application — but others are incoming

Natalie Grover

Reporter

Early in 2019, Bristol-Myers Squibb rescinded an FDA application to market its checkpoint inhibitor Opdivo in combination with its CTLA-4 therapy Yervoy for frontline …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol-Myers withdraws Opdivo/Yervoy lung cancer EU application — but others are incoming

Natalie Grover

Reporter

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Bris­tol-My­ers with­draws Op­di­vo/Yer­voy lung can­cer EU ap­pli­ca­tion — but oth­ers are in­com­ing

Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Bristol-Myers withdraws Opdivo/Yervoy lung cancer EU application — but others are incoming